English | Español
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily Report | May 23, 2023

Dr. Janet Maynard: new FDA-approved drug will 'provide an additional safe and effective option for women' experiencing hot flashes
Patient Daily | May 22, 2023

Vizzia Technologies Achieves SOC 2 Type II Compliance Certification for RTLS
Pacient Daily | May 22, 2023

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Pacient Daily | May 22, 2023

Clinical ink Work Demonstrating Technology Sensitivity to Parkinson’s Disease Published in Nature
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Pacient Daily | May 18, 2023

How OR Automation Keeps Surgeons Busy (and Revenues Up)
Patient Daily Report | May 17, 2023

DBV Technologies CEO: 'We are thrilled to see the EPITOPE Phase 3 data published in the New England Journal of Medicine'

Trending
+ Pharmaceuticals
Patient Daily | Oct 23, 2025

Empower seeks dismissal of Eli Lilly suit in Texas federal court
Patient Daily | Oct 23, 2025

Dallas Breathe Free ENT Specialist: Humidity 'tends to help' with sinus issues
+ Pharmaceuticals
Patient Daily | Oct 29, 2025

Paragon Health Institute senior fellow: 340B program 'needs real reform'
Patient Daily | Oct 23, 2025

Capitol Breathe Free Otolaryngologist: ‘Allergy exacerbations are a common trigger for sinus infections'